3/10/2023 7:14:11 AM
Sol-Gel FY Net Loss $14.9 Mln Or $0.65/Shr Vs Income Of $3.2 Mln Or $0.14/Shr Last Year
4/25/2022 7:31:32 AM
Sol-Gel, Galderma Announce FDA Approval Of EPSOLAY For Inflammatory Lesions Of Rosacea
4/14/2022 8:45:42 AM
Sol-Gel Technologies Announces Commercial Availability Of TWYNEO
12/21/2021 7:34:57 AM
Sol-Gel: FDA Intends To Conduct Pre-approval Inspection Of Production Site For EPSOLAY During The Week Of Feb 14
6/28/2021 5:06:35 AM
Sol-Gel And Galderma Announce Licenses For Commercialization Of EPSOLAY And TWYNEO In U.S.